Last edition
News about "TuHURA Biosciences "
TuHURA Biosciences Files IND for TBS-2025 in Relapsed/Refractory mutNPM1 AML
TuHURA Biosciences has filed an IND with the FDA to evaluate its VISTA-targeting antibody TBS-2025 in combination with a menin inhibitor for relapsed/refractory mutNPM1 AML.
TuHURA Biosciences | 20/02/2026 | By News Bureau | 210
US FDA Grants Orphan Drug Designation to IFx-2.0 of TuHURA Biosciences
TuHURA Biosciences has received FDA Orphan Drug Designation for IFx-2.0 to treat stage IIB–IV cutaneous melanoma, based on data from its completed Phase I study published in Molecular Therapeutics.
TuHURA Biosciences | 04/02/2026 | By News Bureau | 140
TuHURA Biosciences Signs Exclusivity and Right of First Offer Deal for Kineta
TuHURA Biosciences, Inc. has entered into an Exclusivity and Right of First Offer Agreement with Kineta, Inc. for the potential acquisition of Kineta's KVA12123 anti-VISTA antibody and related rights and assets associated with and derived from the asset.
TuHURA Biosciences | 09/07/2024 | By Aishwarya | 627
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy